Open AccessThe implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer
Author(s) -
Jianbo Huang,
Qingqing Luo,
Yun Xiao,
Hongyuan Li,
Lingna Kong,
Guosheng Ren
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.22604
Subject(s) - mapk/erk pathway , triple negative breast cancer , epirubicin , cancer research , medicine , breast cancer , signal transduction , kinase , cancer , biology , microbiology and biotechnology
Triple negative breast cancer (TNBC) is not sensitive to RAS/RAF/ERK signaling pathway (ERK pathway) targeting therapy, due to the absence of excessive activation of ERK pathway. However, the kinase cascades might be activated after chemotherapy in TNBC. Here we aimed to predict whether ERK pathway targeting therapy could be used as an adjuvant therapy in TNBC.